Menopause Hormone Therapy: A Product-Specific Decision Framework

Menopause hormone therapy is not one uniform exposure. Symptom, product, route, formulation, dose, timing, uterus status, contraindications and follow-up all shape a qualified clinical decision.

Use current guidance and current labels

The 2022 Menopause Society position statement describes benefits and risks as varying by type, dose, duration, route, timing and whether a progestogen is used.¹ FDA approved labeling changes for menopausal hormone therapy products in 2026, so older summaries should be checked against current product information.²

The decision components

Indication

Which symptom or clinical goal is being discussed?

Product and route

Use the exact current prescribing information, not a class-wide shortcut.³

Personal context

Age, time since menopause, uterus status, history and preferences affect the conversation.¹

Bring these questions

What symptom or indication is treatment intended to address?
What exact product, route and formulation are being considered?
Which contraindications and individual risk factors apply?
What outcome, adverse effects and follow-up interval will be monitored?
When will the decision be reevaluated?

Reader safety boundary

ACOG’s menopause overview can help orient a symptom discussion, but a symptom list cannot determine personal treatment suitability.⁴ Do not start, stop or change prescription therapy based on this page.

Claim-level evidence

Sources and exact limits

The 2022 hormone therapy position statement of The North American Menopause Society. Professional consensus statement. PMID 35797481. DOI 10.1097/GME.0000000000002028. Design/population: Expert panel review and consensus; Women considering menopause hormone therapy. Limit: Recommendations require individualization; source predates FDA’s 2026 labeling changes. Disclosure: See full statement for panel disclosures. Checked 2026-09-02.
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. FDA regulatory announcement. Design/population: 2026 label-change announcement; Users of affected U.S. products. Limit: Summarizes labeling changes; exact current product labeling controls. Disclosure: Not reported or not applicable. Checked 2026-09-02.
Menopausal Hormone Therapies: Updated Prescribing Information. FDA regulatory source. Design/population: Current product-label collection; Users of affected U.S. products. Limit: Product, route and formulation matter; this is not an individualized benefit-risk decision. Disclosure: Not reported or not applicable. Checked 2026-09-02.
The Menopause Years. Professional medical-society patient guidance. Design/population: Clinical education page; Women in the menopause transition and after menopause. Limit: General educational guidance; a clinician must assess individual symptoms and contraindications. Disclosure: Not reported or not applicable. Checked 2026-09-02.